Nicotinic acetylcholine receptor efficacy and pharmacological properties of 3-(substituted phenyl)-2β-substituted tropanes

Journal of Medicinal Chemistry

Volumn 53, Issue 23, 2010, Pages 8345-8353

  Carroll, F Ivy ^a   Blough, Bruce E ^a   Mascarella, S Wayne ^a   Navarro, Hernán A ^a   Eaton, J Brek ^b   Lukas, Ronald J ^b   Damaj, M Imad ^c  

^a RTI INTERNATIONAL   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALPHA (4 CHLORO 4 METHYLPHENYL)TROPANE 2 BETA CARBOXYLIC ACID METHYL ESTER; 3 ALPHA (4 FLUORO 3 METHYLPHENYL)NORTROPANE 2 BETA CARBOXYLIC ACID METHYL ESTER; 3 BETA (4 CHLORO 3 METHYLPHENYL) 2 BETA (3 METHYLISOXAZOL 5 YL)TROPANE; 3 BETA (4 CHLORO 3 METHYLPHENYL)NORTROPANE 2 BETA CARBOXYLIC ACID METHYL ESTER; 3 BETA (4 CHLOROPHENYL 3 METHYL)TROPANE 2 BETA CARBOXYLIC ACID METHYL ESTER; 3 BETA (4 METHYLPHENYL) 2 BETA (3 ETHYLISOXOAZOL 5 YL)TROPANE; 3 BETA (4 METHYLPHENYL)TROPANE 2 BETA CARBOXYLIC ACID ISOPROPYL ESTER; DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; SEROTONIN; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOTHERMIA; LOCOMOTION; MOUSE; NONHUMAN; SEROTONIN UPTAKE; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; TROPANES;

EID: 78649873024     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100994w     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Smoking and Tobacco Use. Fact Sheet: Health Effects of Cigarette Smoking (updated January 2008). http://www.cdc.gov/tobacco/data-statistics/fact-sheets/health-effects/ effects-cig-smoking/.
2. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States MMWR Morb. Mortal. Wkly. Rep. 2005, 54, 625-628
3. Benowitz, N. L. Nicotine addiction Primary Care: Clin. Office Pract. 1999, 26, 611-631
4. Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction Clin. Pharmacol. Ther. 2008, 83, 531-541
5. Hughes, J. R.; Higgins, S. T.; Bickel, W. K. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities Addiction 1994, 89, 1461-1470
6. Tutka, P.; Mosiewicz, J.; Wielosz, M. Pharmacokinetics and metabolism of nicotine Pharmacol. Rep. 2005, 57, 143-153
7. West, R.; McNeill, A.; Raw, M. Smoking cessation guidelines for health professionals: an update. Health Education Authority Thorax 2000, 55, 987-999
8. Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. I. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 2009, 156, 1178-1184
9. Tutka, P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation Expert Opin. Invest. Drugs 2008, 17, 1473-1485
10. Rollema, H.; Coe, J. W.; Chambers, L. K.; Hurst, R. S.; Stahl, S. M.; Williams, K. E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation Trends Pharmacol. Sci. 2007, 28, 316-325
11. Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Nicotinic receptor-based therapeutics and candidates for smoking cessation Biochem. Pharmacol. 2009, 78, 732-743
12. Carroll, F. I.; Blough, B.; Abraham, P.; Mills, A. C.; Holleman, J. A.; Wolckenhauer, S. A.; Decker, A. M.; Landavazo, A.; McElroy, K. T.; Navarro, H. A.; Gatch, M. B.; Foster, M. J. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction J. Med. Chem. 2009, 52, 6768-6781
13. Dhillon, S.; Yang, L. P.; Curran, M. P. Bupropion: a review of its use in the management of major depressive disorder Drugs 2008, 68, 653-689 (Pubitemid 351484811)
14. Ferris, R. M.; Cooper, B. R. Mechanism of antidepressant activity of bupropion J. Clin. Psychiatry Monog. 1993, 11, 2-14
15. Nielsen, J. A.; Shannon, N. J.; Bero, L.; Moore, K. E. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons Pharmacol., Biochem. Behav. 1986, 24, 795-799
16. Nomikos, G. G.; Damsma, G.; Wenkstern, D.; Fibiger, H. C. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum Neuropsychopharmacology 1992, 7, 7-14
17. Jones, C. N.; Howard, J. L.; McBennett, S. T. Stimulus properties of antidepressants in the rat Psychopharmacology (Berlin) 1980, 67, 111-118
18. Lamb, R. J.; Griffiths, R. R. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine Psychopharmacology (Berlin) 1990, 102, 183-190
19. Ortmann, R. The conditioned place preference paradigm in rats: effect of bupropion Life Sci. 1985, 37, 2021-2027
20. Tella, S. R.; Ladenheim, B.; Cadet, J. L. Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine J. Pharmacol. Exp. Ther. 1997, 281, 508-513
21. Spealman, R. D.; Madras, B. K.; Bergman, J. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior J. Pharmacol. Exp. Ther. 1989, 251, 142-149 (Pubitemid 19261956)
22. Runyon, S. P.; Carroll, F. I. Dopamine transporter ligands: recent developments and therapeutic potential Curr. Top. Med. Chem. 2006, 6, 1825-1843
23. Runyon, S. P.; Carroll, F. I. Tropane-Based Dopamine Transporter-Uptake Inhibitors. In Dopamine Transporters: Chemistry, Biology, and Pharmacology; Trudell, M. L.; Izenwasser, S., Eds.; John Wiley & Sons: Hoboken, NJ, 2008; pp 125 - 169.
24. Lerner-Marmarosh, N.; Carroll, F. I.; Abood, L. G. Antagonism of nicotine's action by cocaine analogs Life Sci. 1995, 56, PL67-PL70
25. Damaj, M. I.; Slemmer, J. E.; Carroll, F. I.; Martin, B. R. Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs J. Pharmacol. Exp. Ther. 1999, 289, 1229-1236
26. Carroll, F. I.; Pawlush, N.; Kuhar, M. J.; Pollard, G. T.; Howard, J. L. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3′-substituted isoxazol-5-yl)tropanes J. Med. Chem. 2004, 47, 296-302
27. Kotian, P.; Mascarella, S. W.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J.; Carroll, F. I. Synthesis, ligand binding, and quantitative structure-activity relationship study of 3β-(4′-substituted phenyl)-2β-heterocyclic tropanes: evidence for an electrostatic interaction at the 2β-position J. Med. Chem. 1996, 39, 2753-2763
28. Carroll, F. I.; Kotian, P.; Dehghani, A.; Gray, J. L.; Kuzemko, M. A.; Parham, K. A.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine and 3β-(4′-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter J. Med. Chem. 1995, 38, 379-388
29. Carroll, F. I.; Mascarella, S. W.; Kuzemko, M. A.; Gao, Y.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 3β-(3′-substituted phenyl)-, 3β-(4′-substituted phenyl)-, and 3β-(3′,4′- disubstituted phenyl)tropane-2β-carboxylic acid methyl esters J. Med. Chem. 1994, 37, 2865-2873
30. Triggle, D. J.; Kwon, Y. W.; Abraham, P.; Rahman, M. A.; Carroll, F. I. Synthesis of 2-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo[3.2.1] octanes and 2 alpha-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8- azabicyclo[3.2.1]oct-2-enes as potential muscarinic agonists Pharm. Res. 1992, 9, 1474-1479
31. Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type J. Pharmacol. Exp. Ther. 1999, 289, 877-885
32. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors Mol. Pharmacol. 2004, 66, 675-682
33. Carroll, F. I.; Blough, B. E.; Mascarella, S. W.; Navarro, H. A.; Eaton, J. B.; Lukas, R. J.; Damaj, M. I. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation J. Med. Chem. 2010, 53, 2204-2214
34. Kota, D.; Martin, B. R.; Robinson, S. E.; Damaj, M. I. Nicotine dependence and reward differ between adolescent and adult male mice J. Pharmacol. Exp. Ther. 2007, 322, 399-407
35. Lukas, R. J.; Muresan, A. Z.; Damaj, M. I.; Blough, B. E.; Huang, X.; Navarro, H. A.; Mascarella, S. W.; Eaton, J. B.; Marxer-Miller, S. K.; Carroll, F. I. Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation J. Med. Chem. 2010, 53, 4731-4748
36. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells Mol. Pharmacol. 2003, 64, 1283-1294
37. Gentry, C. L.; Lukas, R. J. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes J. Pharmacol. Exp. Ther. 2001, 299, 1038-1048
38. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some Methods for Studies of Nicotinic Acetylcholine Receptor Pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, FL, 2002; pp 3 - 27.
39. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 1941, 72, 74-79